Edition:
United States

People: Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

10.16EUR
6:17am EST
Change (% chg)

€0.41 (+4.26%)
Prev Close
€9.75
Open
€10.00
Day's High
€10.20
Day's Low
€9.94
Volume
38,823
Avg. Vol
216,214
52-wk High
€16.20
52-wk Low
€8.21

Fellner, Peter 

Dr. Peter J. Fellner, Ph.D., is Chairman of the Board of Directors of Ablynx NV. since 2013. He is currently Chairman of the Boards of Consort Medical plc and Optos plc. In addition, he serves as Chairman of the biotech company Vernalis plc. He was recently Vice Chairman of Astex Pharmaceuticals Inc, which was acquired in 2013 by Otsuka Pharmaceuticals for US$886 million. He also served as Chairman of Biotie Therapies Corp. from 2010 to 2014, and as a Director of the global biopharmaceutical company UCB from 2005 to 2014, where he continues as a member of the UCB Science Advisory Board. In addition, he is a member of the Novo A/S Advisory Group. Dr Fellner previously served as Chairman of Acambis from 2006 until its acquisition by Sanofi Aventis in 2008, and of Premier Research Group from 2007 to 2008, when it was acquired by a private-equity backed group. He was Chairman of Celltech Group from 2003 to July 2004, until its acquisition for €2.3 billion by UCB, having been CEO from 1990 onwards, during which time he oversaw the Company’s growth from a small research-based company to UK’s largest biotech company. Before joining Celltech, he was CEO of Roche UK from 1986 to 1990. He was nominated Chairman of the Board of Ablynx on 12 November 2013.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --